M. Copeman

发表

Long‐term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study

W. Cosolo, E. Abdi, A. Khalafallah, 2017, European journal of cancer care.

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma

M. Copeman, Michael Copeman, Michael Copeman, 2008, Journal of experimental & clinical cancer research : CR.

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

J. Reynolds, A. Schwarer, J. Seymour, 2005 .

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

H. van de Velde, H. Prince, S. Harrison, 2015, American journal of hematology.

The threshold of malignancy. The roles of oncogenes and anti-oncogenes in cancer.

M. Copeman, 1987, Australian and New Zealand journal of medicine.

High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial

K. Yuen, R. Johnstone, S. Harrison, 2008 .

A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma

Edmond J. Breen, A. Spencer, K. Reed, 2019, Blood Cancer Journal.

The Putative Melanoma Tumor‐Suppressor Gene on Human Chromosome 6q

M. Copeman, M. Copeman, 1992, Pathology.

Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.

J. Szer, H. Prince, D. Joshua, 2010 .

Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (The BoMeR trial): Impact on response and time to progression.

H. Prince, S. Harrison, H. Quach, 2010 .

Death of a clinical trial: a speculative inclusion criterion gone wrong

M. Rosenthal, H. Gurney, H. Woo, 2007, Internal medicine journal.

A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients.

G. Nichol, L. Cohen, A. Spencer, 2010 .

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

M. Keegan, J. Seymour, D. Ritchie, 2007 .

Drug supply and drug abuse.

M. Copeman, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Arterial Brown‐Séquard's syndrome after a penetrating injury of the spinal cord at the cervicomedullary junction

W. Sears, M. Copeman, J. Yeo, 1985, Medical Journal of Australia.